Science with Purpose
“Over the past four years, we’ve focused on implementing our strategy, and we’re seeing how well it is paying off. We’ve delivered new medicines that benefit patients who would otherwise have few or no treatment options while also delivering four years of consecutive growth.”
Launches in 2024
In 2024, Ipsen launched three first- or best-in-class medicines for five diseases.
Bylvay® (odevixibat)
Ipsen conducted the global rollout of this first-in-class treatment for progressive familial intrahepatic cholestasis (PFIC). It is available in the U.S. and Europe as Kayfanda® to treat cholestatic pruritus in Alagille syndrome.
IQIRVO® (elafibranor)
Ipsen received accelerated approval for IQIRVO in the U.S. and Europe as a first-in-class treatment for primary biliary cholangitis (PBC).
Onivyde® (irinotecan)
The Onivyde regimen NALIRIFOX launched in the U.S. as a first-line treatment for adults with metastatic pancreatic adenocarcinoma (mPDAC).
2024 at a glance
Total sales
Sales growth*
*at constant exchange rates (CER)
Investment in R&D
Available firepower for R&D pipeline expansion
Core operating margin
Executing on our strategy in 2024
Innovation
We work relentlessly to bring the full potential of our innovative medicines to patients. This means ensuring access to medicines through regulatory excellence and robust manufacturing processes; and focusing on research and development to identify new potential indications for our medicines.
Sustainable pipeline
We build a high-value sustainable pipeline through an R&D approach that combines internal and external innovation through strategic partnerships. We leverage our end-to-end capabilities to take each molecule through each stage of development, bringing those that succeed as quickly and efficiently as possible to patients.
Efficiencies
We deliver efficiencies to enable targeted investment and growth. We evaluate all activities to ensure they will have an impact for patients and identify potential efficiencies. These are reinvested in R&D, fuel our firepower for external innovation, and support our launch activities.
Culture
We boost a culture of collaboration and excellence. Together, we are Generation Ipsen, a global team united behind our common mission of delivering science with purpose. We prioritize the well-being and health of each member of our teams.
Our people, focused on patients
Patients motivate our people to deliver science with purpose.
Uncategorized
Eva Luna is an energetic little girl who loves to dance and play dress up. She also lives with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease that causes severe itch and can lead to liver failure.
Uncategorized
Anu is the Head of Oncology External Innovation at Ipsen. She and her team work at the forefront of new science and modalities in cancer care.
Uncategorized
Crystel has worked in biomarkers for her entire career. She is proud to contribute to our portfolio of targeted treatments and to increase our expertise in companion diagnostics as our Clinical Biomarker Director.
Uncategorized
Gill, from Nottinghamshire, is devoted to her grandchildren and her garden. She spends her days with her husband and her friends. For more than 20 years, Gill has lived with primary biliary cholangitis (PBC).
Uncategorized
Diana lives in Portugal with her husband and children. When she was 34, she experienced a stroke that left her with spasticity, a condition that causes muscles to become stiff or contract involuntarily.
Therapeutic areas
We focus on three therapeutic areas: Oncology, including complex tumors and rare cancers, Rare Disease such as rare liver and bone conditions, and Neuroscience with innovations in neurotoxins.
Oncology
We pioneer treatments in cancer, advancing bold science where patients have few or no options.
Rare Disease
We are breaking new ground in rare bone and liver diseases, delivering solutions that modify the course of rare diseases and improve the often-debilitating symptoms that impact daily life.
Neuroscience
We are pushing the boundaries of science to deliver neurotoxin innovations, bringing hope to those living with debilitating neurological conditions.
